1Potti A,Mukherjee S,Petersen R,et al.A genomie strategy to refine prognosis in early-stage non-small-cell lung cancer[J].N Engl J Med,2006,355:570-580.
2Olaussen KA,Dunant A,Fouret P,et al.DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].N Engl J Med,2006,355:983-991.
3Paz-Ares LG,Sanchez JM,García-Velasco A,et al.A prospective phase Ⅱ trial of erlotinib in advanced non-small cell lung cancer(NSCLC)patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)[J].J Clin Oncol,2006,24:abstr 7020.
4Cappuzzo F,Toschi L,Tricolini R,et al.Clinical and biological effects of gefitinib in EGFR FISH positive/phosphoakt positive or never smoker non-small cell lung cancer (NSCLC):Preliminary results of the ONCOBELL trial[J].J Clin Oncol,2006,24:abstr 7023.
5Kris MG,Pao W,Zakowski MF,et al.Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy:Preliminary results of the ONCOBELL trial[J].J Clin Oncol,2006,24:abstr 7021.
6Inoue A,Suzuki T,Fukuhara T,et al.Prospective phase Ⅱ study of gefitinib for chemotherapyna? chemotherapynaive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations[J].J Clin Oncol,2006,24:3340-3345.
7Asahina H,Yamazaki K,Kinoshita I,et al.A phase Ⅱ trial of gefitinib as first-line therapy for advanced non-small-cell lung cancer with epidermal growth factor receptor mutations[J].Br J Cancer,2006,95(8):998-1004.
9CHADEYRAS J B, MAZEL C, GRUNENWALD D. Vertebral en bloc resection for lung cancer: twelve years ' experience [ J ]. Ann Chir, 2006,131 (10) :616-622.
10GOLDSTRAW P, CROWLEY J, CHANSKY K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [ J ]. J Thorac Oncol, 2007,2 (8) :706-714.
